| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $161,971,372 | +$38,464,806 | 11,162,741 | +31% | Fairmount Funds Management LLC | 17 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | -11% | $94,411,973 | +$14,637,703 | 4,909,619 | +18% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 5.5% | $38,693,672 | 2,666,690 | VIKING GLOBAL INVESTORS LP | 17 Sep 2025 | |||
| VANGUARD GROUP INC | 5.1% | $74,366,494 | 2,453,530 | The Vanguard Group | 31 Dec 2025 | |||
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 5.2% | $20,429,314 | 1,945,649 | RTW Investments, LP | 31 Mar 2025 |
As of 31 Dec 2025, 89 institutional investors reported holding 18,666,392 shares of Oruka Therapeutics, Inc. - Common stock, $0.001 Par Value (ORKA). This represents 39% of the company’s total 48,355,928 outstanding shares.
The largest institutional shareholders of Oruka Therapeutics, Inc. - Common stock, $0.001 Par Value (ORKA) together control 37% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.3% | 3,539,415 | +61% | 0% | $107,279,669 |
| VANGUARD GROUP INC | 5.1% | 2,453,530 | +38% | 0% | $74,366,494 |
| Deep Track Capital, LP | 4.5% | 2,161,510 | -19% | 1.5% | $65,515,368 |
| Remedium Capital Partners, LLC | 3.2% | 1,552,414 | 0% | 28% | $47,054,000 |
| STATE STREET CORP | 2.9% | 1,383,847 | +112% | 0% | $41,944,403 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 942,507 | +37% | 0% | $28,574,387 |
| FRANKLIN RESOURCES INC | 1.9% | 938,421 | -12% | 0.01% | $28,443,541 |
| Affinity Asset Advisors, LLC | 1.7% | 802,342 | -16% | 1.7% | $24,318,986 |
| Avidity Partners Management LP | 1.4% | 660,424 | 0% | 5.8% | $20,017,451 |
| Synergy Asset Management, LLC | 0.95% | 458,946 | 1.4% | $13,910,653 | |
| SR One Capital Management, LP | 0.89% | 430,330 | 0% | 1.8% | $13,043,302 |
| Candriam S.C.A. | 0.83% | 400,509 | +9.1% | 0.06% | $12,139,945 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.68% | 329,496 | +33% | 0% | $9,987,024 |
| UBS Group AG | 0.56% | 271,013 | +213% | 0% | $8,214,404 |
| Soleus Capital Management, L.P. | 0.39% | 190,000 | 0.24% | $5,758,900 | |
| BARCLAYS PLC | 0.36% | 173,329 | +82% | 0% | $5,253,602 |
| Moody Aldrich Partners LLC | 0.26% | 126,812 | 0.72% | $3,843,672 | |
| MORGAN STANLEY | 0.25% | 122,198 | -9.4% | 0% | $3,703,822 |
| DEUTSCHE BANK AG\ | 0.25% | 119,329 | +439% | 0% | $3,616,862 |
| Kalehua Capital Management LLC | 0.25% | 118,524 | 0% | 3.6% | $3,592,462 |
| Bank of New York Mellon Corp | 0.24% | 114,173 | +62% | 0% | $3,460,584 |
| Alyeska Investment Group, L.P. | 0.21% | 100,000 | 0.01% | $3,031,000 | |
| GOLDMAN SACHS GROUP INC | 0.19% | 92,995 | +370% | 0% | $2,818,678 |
| Nuveen, LLC | 0.18% | 86,347 | +145% | 0% | $2,617,178 |
| Secure Asset Management, LLC | 0.17% | 81,664 | 0.39% | $2,475,247 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 18,666,392 | $565,820,621 | +$129,093,371 | $30.31 | 89 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |